Koshinski Asset Management
ICCC icon

Koshinski Asset Management’s ImmuCell ICCC Stock Holding History

Koshinski Asset Management’s Portfolio ICCC Stock Details ICCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,400
Closed -$13.5K – 1229
2022
Q1 		$13.5K Sell
1,400
-1,000
-42% -$8.63K ﹤0.01% 1524
2021
Q4 		$19.2K Sell
2,400
-500
-17% -$4.47K ﹤0.01% 1461
2021
Q3 		$26.8K Buy
+2,900
New +$27.4K ﹤0.01% 1346

Other funds holding ICCC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
SRC
Shufro Rose & Co New York $1.47B AUM 19.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCM
Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return
OMC
Overbrook Management Corp New York $663M AUM 35.04% 1-Year Est. Return
SFS
Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Koshinski Asset Management's ICCC Position: Q2 2022 in Review

Koshinski Asset Management sold out of ImmuCell (ICCC) in Q2 2022, closing a stake of 1,400 shares — an estimated $13.5K sold.

Koshinski Asset Management first reported a position in ICCC in Q3 2021 and held it in 3 quarters. The position peaked at $26.8K in Q3 2021. 29 funds tracked by Wall St. Rank hold ICCC as of Q2 2022.

  • Koshinski Asset Management reported no remaining ImmuCell position as of Q2 2022 after selling out during the quarter.
  • Koshinski Asset Management sold 1,400 ImmuCell shares in Q2 2022, an estimated $13.5K.
  • Koshinski Asset Management first reported a position in ImmuCell in Q3 2021 and held it in 3 quarters.
  • Koshinski Asset Management's ImmuCell position peaked at $26.8K in Q3 2021.
  • 29 funds tracked by Wall St. Rank held ImmuCell as of Q2 2022.

Based on Koshinski Asset Management's 13F filing for Q2 2022, filed 12 Jul 2022.